Lieve Oudejans

Lieve Oudejans, MSc, is an active researcher specializing in Acute Myeloid Leukemia (AML) with a focus on metabolic and cellular mechanisms. Her work bridges nanotechnology, lipid metabolism, and cell death pathways to identify therapeutic vulnerabilities in leukemia.

Education:

• MSc (field unspecified)

Her research centers on three critical AML pathways:

• Lipid metabolism dysregulation, particularly fatty acid desaturation via Stearoyl-CoA desaturase 1 (SCD1)
• Nanoparticle-mediated interactions between stromal membrane particles and leukemia cells
• Cysteine-dependent regulation of ferroptosis (iron-mediated cell death)

Recent publications (2024-2025) reveal a cohesive trend toward targeting metabolic dependencies in AML, with strong emphasis on translational applications of nanomedicine and lipid biochemistry. This work positions metabolic inhibitors and nano-delivery systems as promising therapeutic avenues.

No scientific awards or major grants are documented. Collaborative work occurs primarily within Prof. Schuringa's research group, though specific lab structures or advisory roles remain unreported.